193 related articles for article (PubMed ID: 9815789)
1. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
[TBL] [Abstract][Full Text] [Related]
2. The minimal effective exemestane dose for endocrine activity in advanced breast cancer.
Bajetta E; Zilembo N; Noberasco C; Martinetti A; Mariani L; Ferrari L; Buzzoni R; Greco M; Bartoli C; Spagnoli I; Danesini GM; Artale S; Paolini J
Eur J Cancer; 1997 Apr; 33(4):587-91. PubMed ID: 9274439
[TBL] [Abstract][Full Text] [Related]
3. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.
Geisler J; King N; Anker G; Ornati G; Di Salle E; Lønning PE; Dowsett M
Clin Cancer Res; 1998 Sep; 4(9):2089-93. PubMed ID: 9748124
[TBL] [Abstract][Full Text] [Related]
4. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of vorozole (R83842), a new aromatase inhibitor, in postmenopausal women with advanced breast cancer in progression on tamoxifen.
Goss PE; Clark RM; Ambus U; Weizel HA; Wadden NA; Crump M; Walde D; Tye LM; De Coster R; Bruynseels J
Clin Cancer Res; 1995 Mar; 1(3):287-94. PubMed ID: 9815984
[TBL] [Abstract][Full Text] [Related]
6. Influence of dexaminoglutethimide, an optical isomer of aminoglutethimide, on the disposition of estrone sulfate in postmenopausal breast cancer patients.
Geisler J; Lundgren S; Berntsen H; Greaves JL; Lønning PE
J Clin Endocrinol Metab; 1998 Aug; 83(8):2687-93. PubMed ID: 9709932
[TBL] [Abstract][Full Text] [Related]
7. Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.
Evans TR; Di Salle E; Ornati G; Lassus M; Benedetti MS; Pianezzola E; Coombes RC
Cancer Res; 1992 Nov; 52(21):5933-9. PubMed ID: 1394219
[TBL] [Abstract][Full Text] [Related]
8. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.
Lundgren S; Helle SI; Lonning PE
Clin Cancer Res; 1996 Sep; 2(9):1515-21. PubMed ID: 9816328
[TBL] [Abstract][Full Text] [Related]
9. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
Love RR; Hutson PR; Havighurst TC; Cleary JF
Clin Cancer Res; 2005 Feb; 11(4):1500-3. PubMed ID: 15746052
[TBL] [Abstract][Full Text] [Related]
10. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Hutson PR; Love RR; Havighurst TC; Rogers E; Cleary JF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8722-7. PubMed ID: 16361559
[TBL] [Abstract][Full Text] [Related]
11. Exemestane (FCE 24304), a new steroidal aromatase inhibitor.
di Salle E; Ornati G; Giudici D; Lassus M; Evans TR; Coombes RC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):137-43. PubMed ID: 1525055
[TBL] [Abstract][Full Text] [Related]
12. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.
Jones S; Vogel C; Arkhipov A; Fehrenbacher L; Eisenberg P; Cooper B; Honig S; Polli A; Whaley F; di Salle E; Tiffany J; Consonni A; Miller L
J Clin Oncol; 1999 Nov; 17(11):3418-25. PubMed ID: 10550136
[TBL] [Abstract][Full Text] [Related]
13. Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study.
Paridaens R; Thomas J; Wildiers J; Vermeiren P; Lobelle JP; di Salle E; Ornati G; Zurlo MG; Polli A; Lanzalone S; de Belder K
Anticancer Drugs; 1998 Sep; 9(8):675-83. PubMed ID: 9823425
[TBL] [Abstract][Full Text] [Related]
14. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples.
Geisler J; Ekse D; Helle H; Duong NK; Lønning PE
J Steroid Biochem Mol Biol; 2008 Mar; 109(1-2):90-5. PubMed ID: 18242079
[TBL] [Abstract][Full Text] [Related]
15. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Rivera E; Valero V; Francis D; Asnis AG; Schaaf LJ; Duncan B; Hortobagyi GN
Clin Cancer Res; 2004 Mar; 10(6):1943-8. PubMed ID: 15041710
[TBL] [Abstract][Full Text] [Related]
16. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
Robarge JD; Desta Z; Nguyen AT; Li L; Hertz D; Rae JM; Hayes DF; Storniolo AM; Stearns V; Flockhart DA; Skaar TC; Henry NL
Breast Cancer Res Treat; 2017 Feb; 161(3):453-461. PubMed ID: 27943008
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Traina TA; Poggesi I; Robson M; Asnis A; Duncan BA; Heerdt A; Dang C; Lake D; Moasser M; Panageas K; Borgen P; Norton L; Hudis C; Dickler MN
Breast Cancer Res Treat; 2008 Sep; 111(2):377-88. PubMed ID: 17952589
[TBL] [Abstract][Full Text] [Related]
18. Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients.
Lønning PE; Johannessen DC; Lien EA; Ekse D; Fotsis T; Adlercreutz H
J Steroid Biochem Mol Biol; 1995 May; 52(5):491-6. PubMed ID: 7748814
[TBL] [Abstract][Full Text] [Related]
19. Exemestane in postmenopausal women with early or advanced breast cancer: a review.
Bertelli G; Gangadhara S
Expert Opin Pharmacother; 2010 Aug; 11(11):1933-42. PubMed ID: 20569090
[TBL] [Abstract][Full Text] [Related]
20. Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients.
Geisler J; Haynes B; Anker G; Helle H; Ekse D; Dowsett M; Lønning PE
J Steroid Biochem Mol Biol; 2005 Sep; 96(5):415-22. PubMed ID: 16168635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
